CorMedix (CRMD) EBITDA (2010 - 2025)

CorMedix (CRMD) has 16 years of EBITDA data on file, last reported at $59.1 million in Q4 2025.

• For the quarter ending Q4 2025, EBITDA rose 357.05% year-over-year to $59.1 million; the trailing twelve-month figure through Dec 2025 stood at $150.1 million (up 771.59% YoY), and the FY2025 full-year result was $150.1 million, up 771.59% from the prior year.
• EBITDA improved to $59.1 million in Q4 2025, from $51.3 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $59.1 million in Q4 2025 to a low of -$16.7 million in Q1 2024.
• A 5-year average of $938282.8 and a median of -$7.5 million in 2021 frame the typical range for EBITDA.
• Across the five-year window, EBITDA slumped 86.77% in 2023 and surged 1661.93% in 2025, its largest moves.
• Tracing CRMD's EBITDA over 5 years: stood at -$7.8 million in 2021, then dropped by 7.83% to -$8.4 million in 2022, then plunged by 86.77% to -$15.7 million in 2023, then surged by 182.56% to $12.9 million in 2024, then surged by 357.05% to $59.1 million in 2025.
• Business Quant data shows CRMD's EBITDA at $59.1 million in Q4 2025, $51.3 million in Q3 2025, and $19.5 million in Q2 2025.